Milestone Scientific, Inc. (OTCBB:MLSS)Press Release
For more information, please contact:
Elite Financial Communications Group, LLC
Dodi Handy, President and CEO, or
Daniel Conway, Chief Strategist
407-585-1080 or via email at mlss@efcg.net
Milestone Scientific To Exhibit At The 2007 Infection Control And Safety Boot Camp
January 19, 2007
Companies to Co-Develop Painless Injection Solution, Based on Milestone's
Patented CompuFlo Technology, to Address $21 Billion Osteoarthritis Market
LIVINGSTON, NJ – (PR NEWSWIRE) – January 19, 2007 – Milestone Scientific, Inc. (OTCBB:MLSS), the recognized leader in advanced injection technologies used by medical and dental professionals worldwide, today announced that it will be exhibiting at the upcoming Infection Control and Safety Boot Camp hosted by the Organization for Safety and Asepisis Procedures.
WHEN: January 22-25, 2007
WHERE: Booth # 2206, Crowne Plaza Atlanta-Ravinia Hotel, 4355 Ashford Dunwoody, Atlanta, GA 30346
WHAT: Learn first hand how Milestone is defining a new standard of excellence in localized drug injections.
OSAP is the Organization for Safety and Asepsis Procedures. Founded in 1984, the non-profit association is dentistry's premier resource for infection control and safety information. Through its publications, courses, website, and worldwide collaborations, OSAP and the tax-exempt OSAP Foundation support education, research, service, and policy development to promote safety and the control of infectious diseases in dental healthcare settings worldwide. For more information, call (800) 298-OSAP (6727) or go to www.OSAP.org.
About Milestone Scientific, Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific, Inc. has developed and currently manufactures, markets and sells a proprietary, patented computer-controlled system for the improved and painless delivery of local anesthetic. The system is marketed in Dentistry under the trademark "CompuDent" and in Medicine under the trademark "CompuMed". CompuDent™ is suitable for all dental procedures, while CompuMed™ is suitable for many medical procedures regularly used in Plastic Surgery, Hair Restoration Surgery, Podiatry, Colorectal Surgery, Dermatology, Orthopedics, and a number of other disciplines. CompuDent and CompuMed are sold in the United States and worldwide in over 25 countries. Both systems comprise a microprocessor-controlled drive unit as well as The Wand® handpiece, a single patient use product that is held in a pen-like manner for injections. The Company also sells the SafetyWand®, which incorporates engineered sharps injury protection features to aid in the prevention of accidental needle sticks. Milestone has also developed proprietary consumer (Ionic White™) and professional (CoolBlue™) teeth whitening systems.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2006. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.